Is IBRX up or down today?
IBRX is down 2.01% today, last at 6.83. This stock moved -2.01% versus the prior close.
IBRX · IBRX
IBRX (IBRX) is trading at 6.83, down 2.01% on the session. Price action shows weakness or stretched conditions worth watching.
Over the past 7 days, 23 headlines skew mixed. Earnings and Macro/Market themes dominated coverage. Stories with measurable price impact averaged -8.46% — headlines dragged the stock.
Social mentions lean cautious or negative.
Analyst firms are mostly reiterating — no strong directional shift lately.
IBRX is down 2.01% today, last at 6.83. This stock moved -2.01% versus the prior close.
Over the past 7 days, 23 headlines skew mixed. Earnings and Macro/Market themes dominated coverage. Stories with measurable price impact averaged -8.46% — headlines dragged the stock. Dominant story: ImmunityBio Receives United Arab Emirates (UAE) Marketing Authorization for ANKTIVA® Across BCG-Unresponsive Non-Muscle Invasive Bladder Cancer for CIS and Papillary Disease and Metastatic Non-Small Cell Lung Cancer (1 source, neutral) RSI is 37 — leaning bearish Price below 50-day average — short-term weakness Social (demo): 38% of recent mentions lean bullish — social mood is cautious.
Loaded: Jan 2026 – Jul 2026 (124 days) · Drag or scroll left for earlier dates
Analyst firms are mostly reiterating — no strong directional shift lately.
Query: IBRX
31/ 100 index
-43.6% vs start of window
Based on 12,385 mentions over 30d
ImmunityBio Receives United Arab Emirates (UAE) Marketing Authorization for ANKTIVA® Across BCG-Unresponsive Non-Muscle Invasive Bladder Cancer for CIS and Papillary Disease and Metastatic Non-Small Cell Lung Cancer
IBRX Stock Extends 5-Day Losing Streak — Retail Traders Pin Hopes On ‘Incredibly Strong’ Anktiva Sales And Earnings Beat - Stocktwits
IBRX Stock Extends 5-Day Losing Streak — Retail Traders Pin Hopes On ‘Incredibly Strong’ Anktiva Sales And Earnings Beat
Immunitybio Inc (IBRX) Institutional Confidence - TradingKey
IBRX Stock Climbs After-Hours: Retail Traders Bet Russell 1000 Inclusion Could Trigger Massive Index-Fund Buying - Stocktwits